Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which diabetes pill combo works best? new study pits three options Head-to-Head

NCT ID NCT06759922

Disease control Sponsor: Bahria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested different combinations of diabetes drugs (glimepiride, empagliflozin, or sitagliptin) taken with metformin in 172 adults newly diagnosed with type 2 diabetes. Participants were split into four groups and took their assigned pills once daily for 90 days. Researchers measured blood sugar control (HbA1c), weight, cholesterol, and side effects to see which combination worked best and was safest.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin combined with glimepiride, empagliflozin, or sitagliptin
What this could lead to
If successful, this could help doctors choose the most effective and safe two- or three-drug combination for managing blood sugar in newly diagnosed type 2 diabetes patients.
What could go wrong
This is a small, completed Phase 4 trial, so results may not apply to all patients. Side effects like diarrhea, weight gain, or urinary infections are possible with these drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

172 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females * Age 30-55yrs * HbA1c = ≥ 8.5 \<10 mmol/mol (ADA. 2018) * BMI \>18.5- \<29.9 (WHO Asian Criteria) * Treatment naïve patients * With / without dyslipidemia. Exclusion Criteria: * HbA1c \>10 mmol/mol * BMI \> 30 * Pregnancy or lactation * Systemic diseases such as: hypertension, thyroid, liver, renal diseases etc. * Known allergy or intolerance to Metformin, Glimepiride, Sitagliptin or Empagliflozin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • National Medical Center

    Karachi, Sindh, 75500, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.